BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect.

BJE6-106 (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing JNK, MKK4, and H2AX activation at different times in SBcl2 cells.

1564249-38-2

C26H23NO2

381.47

B106;BJE6-106

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years